摘要
目的探讨大鼠糖尿病动物模型建立及参芪复方干预作用机制。方法选择2017年2月—2018年1月参加实验的SD大鼠50只,随机取10只设为空白对照组。剩余40只大鼠采用链脲佐菌素(STZ)腹腔注射联合高脂饮食建立大鼠糖尿病动物模型。建模成功后随机取10只,设为模型对照组;剩余30只大鼠给予参芪复方干预,根据药物剂量分为低剂量组(n=10只)、中剂量组(n=10只)和高剂量组(n=10只)。空白对照组与模型对照组均给予10 mL/kg等剂量生理盐水灌胃,低剂量组给予0.72 mg/(kg·d)参芪复方(成人等效剂量),中剂量组给予1.58 mg/(kg·d)参芪复方(成人等效剂量2倍),高剂量组给予2.88 mg/(kg·d)参芪复方(成人等效剂量4倍),连续干预42 d,干预完毕后对大鼠效果进行评估,比较各组干预效果。结果中剂量组干预后14、28、42 d血糖水平分别为[(23.25±1.70)、(18.57±1.99)、(15.34±1.65)mmol/L],均低于低剂量组(25.44±1.73)、(22.40±3.32)、(24.00±1.74)mmol/L]与高剂量组[(25.48±1.78)、(22.41±3.25)、(23.99±1.73)mmol/L](F=5.395、7.841、4.709,P<0.05),低剂量组、中剂量组、高剂量组干预后14、28、42 d血糖水平,均低于模型对照组(26.48±2.99)、(27.12±3.04)、(27.09±3.01)(P<0.05);低剂量组、中剂量组、高剂量组TC[(1.53±0.17)、(1.24±0.21)、(1.54±0.18)mmol/L、TG(0.67±0.15)、(0.51±0.14)、(0.68±0.16)mmol/L]及LDL-C[(0.31±0.09)、(0.21±0.08)、(0.32±0.09)mmol/L]水平,均低于模型对照组(P<0.05),高于空白对照组(P<0.05)。结论利用STZ腹腔注射联合高脂饮食能成功建立糖尿病大鼠模型,给予中剂量参芪复方有助于控制大鼠血糖水平,改善血脂代谢,值得推广应用。
Objective To investigate the establishment of animal model of diabetes in rats and the intervention mechanism of Shenqi compound. Methods A total of 50 SD rats who participated in the experiment from February 2017 to January 2018 were randomly se-lected and placed in a blank control group. The remaining 40 rats were cultured with a streptozotocin（STZ） intraperitoneal injection combined with a high-fat diet to establish a rat model of diabetes. After successful modeling, 10 rats were randomly selected and set as model control group; the remaining 30 rats were given intervention with Shenqi compound, and divided into low dose group（ n=10）and middle dose group（n=10） according to drug dosage. And high dose group（n=10）.And high dose group（n=10）. The blank control group and the model control group were given the same dose of 10 mL/kg normal saline. The low dose group was given 0.72 mg/（kg·d）Shenqi compound（adult equivalent dose）, and the middle dose group was given 1.58 mg/（kg·d） Shenqi compound（two times equivalent dose for adults）, high dose group 2.88 mg/（kg·d） Shenqi compound（an equivalent dose of 4 times for adults）, compound for 42 days. After the intervention, the effects of the rats were evaluated and the effects of each group were compared. Results The blood glu-cose levels at 14, 28 d and 42 d after intervention in the middle dose group were [（23.25 ±1.70）,（18.57±1.99）,（15.34±1.65）mmol/L],respectively, which were lower than those in the low dose group [（25.44±1.73）,（22.40±3.32）,（24.00±1.74）mmol/L] and high. The dose group [（25.48±1.78）,（22.41±3.25）,（23.99±1.73）mmol/L]（F=5.395, 7.841, 4.709, P〈0.05）, low-dose group, middle-dose group, high-dose group, blood glucose level at 14 d, 28 d, 42 d after intervention, All were lower than the model control group[（26.48±2.99）,（27.12±3.04）,（27.09 ±3.01）（P〈0.05）; low dose group, middle dose group, high dose group TC [（1.53 ±0.17）,（1.24 ±0.21）,（1.54 ±0.18） mmol/L], TG[（0.67±0.15）,（0.51±0.14）,（0.68±0.16） mmol/L] and LDL-C [（0.31±0.09）,（0.21±0.08）,（0.32±0.09） mmol/L] were lower than the model control group（P〈0.05）, higher than the blank control group（P〈0.05）. Conclusion The diabetic rat model can be successfully established by intraperitoneal injection of STZ combined with high-fat diet. The administration of medium-dose Shenqi compound can help control blood sugar level and improve blood lipid metabolism in rats, which is worthy of popularization and application.
作者
林文东
李振喜
施水液
张美佳
LIN Wen-dong;LI Zhen-xi;SHI Shui-ye;ZHANG Mei-jia(Department of Basic Medicine,Quanzhou Medical College,Quanzhou,Fujian Province,362000 China;Jinjiang City Hospital of Integrated Traditional Chinese and Western Medicine,Jinjiang,Fujian Province,362200 China)
出处
《世界复合医学》
2018年第3期11-13,共3页
World Journal of Complex Medicine
